Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Laboratory expansion to large-scale international HIV preventive vaccine trials

Laboratory expansion to large-scale international HIV preventive vaccine trials Laboratory expansion to large-scale international HIV preventive vaccine trials a b c d Jill W. Gilmour , Wendy S. Stevens , Clive Gray and Mark de Souza Purpose of review Introduction The purpose of this article is to describe the requirements Clinical trials of prophylactic AIDS vaccine candidates for clinical laboratories supporting large-scale multinational are challenging but feasible in both the developed and trials of prophylactic AIDS vaccine trials and review the developing world [1 ]. Phase IIb test of concept (TOC) progress made. trials [2 ,3] or phase III efficacy trials, involving large Recent findings numbers of volunteers at risk of HIV infection, will There is an increasing need for laboratories in Africa, Asia be conducted in several developing countries where and the Caribbean to support internationally initiated and the need for a preventive vaccine is compelling and funded clinical trials of preventive HIV vaccine candidates. the highest incidence of HIV is found [4,5,6 ]. This poses A number of qualified laboratories are currently supporting a new paradigm for the licensing of a vaccine that has AIDS vaccine trials in these regions, although there remains been tested in a developing country in its initial efficacy a need to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Laboratory expansion to large-scale international HIV preventive vaccine trials

de Souza, Mark
Current Opinion in HIV and Aids , Volume 2 (3) – May 1, 2007
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/laboratory-expansion-to-large-scale-international-hiv-preventive-2WbVaAQR1l

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e3280eec77a
pmid
19372887
Publisher site
See Article on Publisher Site

Abstract

Laboratory expansion to large-scale international HIV preventive vaccine trials a b c d Jill W. Gilmour , Wendy S. Stevens , Clive Gray and Mark de Souza Purpose of review Introduction The purpose of this article is to describe the requirements Clinical trials of prophylactic AIDS vaccine candidates for clinical laboratories supporting large-scale multinational are challenging but feasible in both the developed and trials of prophylactic AIDS vaccine trials and review the developing world [1 ]. Phase IIb test of concept (TOC) progress made. trials [2 ,3] or phase III efficacy trials, involving large Recent findings numbers of volunteers at risk of HIV infection, will There is an increasing need for laboratories in Africa, Asia be conducted in several developing countries where and the Caribbean to support internationally initiated and the need for a preventive vaccine is compelling and funded clinical trials of preventive HIV vaccine candidates. the highest incidence of HIV is found [4,5,6 ]. This poses A number of qualified laboratories are currently supporting a new paradigm for the licensing of a vaccine that has AIDS vaccine trials in these regions, although there remains been tested in a developing country in its initial efficacy a need to

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: May 1, 2007

There are no references for this article.